ABSTRACT
AIM: Intrahepatic cholestasis of pregnancy (ICP) is considered a high-risk condition because it may have serious consequences for the fetus health. ICP is characterized by the accumulation of bile acids in maternal serum which contribute to an imbalance between the production of reactive oxygen species and the antioxidant defenses increasing the oxidative stress experienced by the fetus. Previously, it was reported a significant decrease in plasma coenzyme Q10 (CoQ10) in women with ICP. CoQ10 is a redox substance integrated in the mitochondrial respiratory chain and is recognized as a potent antioxidant playing an intrinsic role against oxidative damage. The objective of the present study was to investigate the levels of CoQ10 in umbilical cord blood during normal pregnancy and in those complicated with ICP, all of them compared to the maternal ones. METHODS: CoQ10 levels and bile acid levels in maternal and umbilical cord blood levels during normal pregnancies (n=23) and in those complicated with ICP (n=13), were investigated. RESULTS: A significant decrease in neonate CoQ10 levels corrected by cholesterol (0.105±0.010 vs. 0.069±0.011, P<0.05, normal pregnancy vs. ICP, respectively), together with an increase of total serum bile acids (2.10±0.02 vs. 7.60±2.30, P<0.05, normal pregnancy vs. ICP, respectively) was observed. CONCLUSIONS: A fetus from an ICP mother is exposed to a greater risk derived from oxidative damage. The recognition of CoQ10 deficiency is important since it could be the starting point for a new and safe intervention strategy which can establish CoQ10 as a promising candidate to prevent the risk of oxidative stress.
Subject(s)
Ataxia/blood , Bile Acids and Salts/blood , Cholestasis, Intrahepatic/blood , Fetal Blood/chemistry , Mitochondrial Diseases/blood , Muscle Weakness/blood , Pregnancy Complications/blood , Ubiquinone/analogs & derivatives , Ubiquinone/deficiency , Adult , Ataxia/diagnosis , Biomarkers/blood , Birth Weight , Cholesterol/blood , Cholic Acid/blood , Cross-Sectional Studies , Female , Fetus/metabolism , Gestational Age , Humans , Infant, Newborn , Mitochondrial Diseases/diagnosis , Muscle Weakness/diagnosis , Oxidation-Reduction , Oxidative Stress , Pregnancy , Prospective Studies , Reactive Oxygen Species/metabolism , Ubiquinone/blood , Young AdultABSTRACT
Coenzyme Q10 (CoQ10) is an important cofactor in the mitochondrial respiratory chain and a potent endogenous antioxidant. CoQ10 deficiency is often associated with numerous diseases, and patients can benefit from CoQ10 supplementation, being more effective when diagnosed and treated early. Due to the increased interest in CoQ10 deficiency, several methods for CoQ10 analysis from plasmatic, muscular, fibroblast, and platelet matrices have been developed. These sampling techniques are not only highly invasive but also too traumatic for periodic clinical monitoring. In the present work, we describe the development and validation of a novel non-invasive sampling method for quantification of CoQ10 in buccal mucosa cells (BMCs) by microHPLC. This method is suitable for using in a routine laboratory and useful for sampling patients in pediatry. CoQ10 correlation was demonstrated between BMCs and plasma levels (Spearman r, 0.4540; p < 0.001). The proposed method is amenable to be applied in the post treatment monitoring, especially in pediatric patients as a non-invasive sample collection. More studies are needed to assess whether this determination could be used for diagnosis and if this matrix could replace the traditional ones.
Subject(s)
Ataxia/diagnosis , Chromatography, High Pressure Liquid/methods , Mitochondrial Diseases/diagnosis , Mouth Mucosa/cytology , Muscle Weakness/diagnosis , Ubiquinone/analogs & derivatives , Ubiquinone/deficiency , Adult , Ataxia/blood , Child , Humans , Limit of Detection , Mitochondrial Diseases/blood , Muscle Weakness/blood , Ubiquinone/analysis , Ubiquinone/bloodABSTRACT
Recent studies have shown that antiganglioside antibodies, particularly those associated with the disialosyl group, may be involved in immune-mediated sensory peripheral neuropathies. We report the results of plasma screening for antiganglioside antibodies in two patients with chronic ataxic neuropathy. We found reactivity against gangliosides GD3, GD1b, and GT1b in one of them and against GD1a in the other, even though both had nearly identical clinical pictures. Results suggest that anti-GD1a antibodies, which are usually associated with motor polyneuropathy, may also be involved in the pathogenesis of clinically pure sensory polyneuropathy.
Subject(s)
Antibodies/blood , Ataxia/immunology , Gangliosides/immunology , Adult , Ataxia/blood , Chronic Disease , Extremities , Gangliosides/blood , Humans , MaleABSTRACT
Recent studies have shown that antiganglioside antibodies, particularly those associated with the disialosyl group, may be involved in immune-mediated sensory peripheral neuropathies. We report the results of plasma screening for antiganglioside antibodies in two patients with chronic ataxic neuropathy. We found reactivity against gangliosides GD3, GD1b, and GT1b in one of them and against GD1a in the other, even though both had nearly identical clinical pictures. Results suggest that anti-GD1a antibodies, which are usually associated with motor polyneuropathy, may also be involved in the pathogenesis of clinically pure sensory polyneuropathy (AU)#S#a